If Cabo gets approved for prostate cancer it could go up 5 fold.
I don't see anything new about this study, which ends in 2014. I think EXEL has a lot of upside but that alone will not get the stock to 24.
Sentiment: Strong Buy
MDVN with Xtandi having on one indication (prostate ca) went to ~$100 PPS. Even though EXEL's stock is much more diluted I would think Comet1 and maybe 1-2 other indications (RCC, HCC) this could be $50 PPS.
Of course I agree with you. They need to earn a lot more milestones and get stellar data on some of their other trials.